News -
Check out the posts below to learn the latest updates on our progress
- June 16 2020EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of DirectorsPRNewswire
- May 12 2020Let’s Get the CAR-T Started
Longevity Technology - April 15 2020Chairman & CEO Greg Frost on the Empowered Patient podcast with Karen Jagodahttp://empoweredpatientradio.com/
- March 12 2020F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular TherapiesPRNewswire
- April 3 2019Same Day Transduction and In Vivo Expansion of a Chimeric Antigen Receptor with a Synthetic Driver Construct for Adoptive Cellular Therapy
AACR 2019 - April 3 2019A High-Throughput Screening Strategy for the Identification of Novel Lymphoproliferative Elements
AACR 2019 - April 3 2019CAB-CAR-T: The Prioritization of Cell Surface Protein Targets for Conditionally Active Biologics to Treat All Solid Tumors
AACR 2019 - April 3 2019A Novel Conditionally Active Biologics Approach to Minimize On-target Off-tumor Effects in Adoptive Immunotherapy
AACR 2019 - March 31 2019F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
Business Wire - March 29 2019Taking the Next Step: What We’ve Learned About CAR-T So Far, and What It Means Going Forward
